Cannabis firm to pay $4 million for stake in Vancouver biotech

CannaRoyalty Corp. to acquire 20% stake in Anandia Laboratories
Anandia Labs co-founder Jonathan Page agreed to sell 20% of his company to CannaRoyalty because he likes CannaRoyalty's expertise in extraction and post-processing | Chung Chow

With the federal government on the verge of legalizing marijuana, high-value strategic assets in the cannabis sector are becoming valuable.

That is how Ottawa-based cannabis firm CannaRoyalty Corp. explained its interest in buying a 20% stake in Vancouver’s Anandia Laboratories.

The companies announced January 9 that they have signed a letter of intent for CannaRoyalty (CSE:CRZ) to acquire that 20% stake in Anandia for $4 million.

Anandia is a biotechnology company that tests medical marijuana and uses genomics for plant breeding. It has completed extensive research into cannabis genetics and has built a significant intellectual-property position that includes cannabinoid pathway patents, according to the company.

Anandia also been issued a dealers licence from Health Canada pursuant to the provisions of the Controlled Drugs and Substances Act and the Narcotic Control Regulations.

This dealers licence allows Anandia to analyze and extract cannabis, and cultivate cannabis for breeding and strain improvement. This licensing gives Anandia the ability to do research and development, and develop products that would not otherwise be permitted for licensed

producers under Health Canada’s Access to Cannabis for Medical Purposes Regulations.

Because pesticide use is a concern in any product consumed by humans, Anandia also plans to use genomics to develop pest-resistant strains.

“We have elected to partner with CannaRoyalty given their expertise in extraction, post-processing and the development of proprietary formulations,” said Anandia co-founder Jonathan Page.

CannaRoyalty is a fully integrated, active investor and operator in the legal cannabis sector. It intends to build and support a diversified portfolio of assets that it thinks will grow in value as marijuana legalization becomes reality in Canada.

Some of these assets are research, consumer brands, devices and intellectual property.

Genome BC last fall announced that it had invested $500,000 in Anandia.

gkorstrom@biv.com 

@GlenKorstrom 

comments powered by Disqus

More from Technology

AI recruitment woes stall B.C. business expansion plans

Province lost nearly 300 software professionals to other regions in 2016 as AI funding flees

Read Article

Ballard Power Systems tests new hydrogen fuel cell for major U.S. surveillance ...

Read Article

Land valuator boss keeps company on crest of big-data wave

Profile: Jeff Tisdale, CEO, Landcor Data Corp.

Read Article

Global, local life sciences funds set up shop in city

Vancouver fund investing US$500m globally; Toronto fund to focus on local startups

Read Article

Infographic: 17 first things to ever happen on the Internet

Long before Google, there was Archie. This infographic breaks down some big Internet ‘firsts’

Read Article

Subscribe to our mailing lists

* indicates required

Newsletters

* You can modify your newsletter subscriptions at the bottom of any newsletter you receive.
×